These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36031049)

  • 1. T cell abnormalities in systemic sclerosis.
    Jin W; Zheng Y; Zhu P
    Autoimmun Rev; 2022 Nov; 21(11):103185. PubMed ID: 36031049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imbalance between T helper 17 and regulatory T cell subsets plays a significant role in the pathogenesis of systemic sclerosis.
    Mo C; Zeng Z; Deng Q; Ding Y; Xiao R
    Biomed Pharmacother; 2018 Dec; 108():177-183. PubMed ID: 30219674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Pathophysiological Roles of Regulatory T Cells in the Early Phase of Systemic Sclerosis.
    Kobayashi S; Nagafuchi Y; Shoda H; Fujio K
    Front Immunol; 2022; 13():900638. PubMed ID: 35686127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T cell abnormalities in systemic sclerosis with a focus on Th17 cells.
    Brembilla NC; Chizzolini C
    Eur Cytokine Netw; 2012; 23(4):128-39. PubMed ID: 23360781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of Th17 cells and CD4⁺CD25⁺ regulatory T cells with clinical parameters in patients with systemic sclerosis.
    Jiang N; Li M; Zeng X
    Chin Med J (Engl); 2014; 127(20):3557-61. PubMed ID: 25316229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New insights into CD4(+) T cell abnormalities in systemic sclerosis.
    Liu M; Wu W; Sun X; Yang J; Xu J; Fu W; Li M
    Cytokine Growth Factor Rev; 2016 Apr; 28():31-6. PubMed ID: 26724976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory T cells produce profibrotic cytokines in the skin of patients with systemic sclerosis.
    MacDonald KG; Dawson NAJ; Huang Q; Dunne JV; Levings MK; Broady R
    J Allergy Clin Immunol; 2015 Apr; 135(4):946-955.e9. PubMed ID: 25678090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions.
    Mathian A; Parizot C; Dorgham K; Trad S; Arnaud L; Larsen M; Miyara M; Hié M; Piette JC; Frances C; Yssel H; Amoura Z; Gorochov G
    Ann Rheum Dis; 2012 Jul; 71(7):1227-34. PubMed ID: 22696687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of thalidomide on Th17, Treg cells and TGF-β1/Smad3 pathway in a mouse model of systemic sclerosis.
    Lu Y; Zhao C; Lei L; Tao Z; Zheng L; Wen J; Li X
    Int J Rheum Dis; 2020 Mar; 23(3):406-419. PubMed ID: 31840939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Th17 and regulatory T lymphocytes in primary biliary cirrhosis and systemic sclerosis as models of autoimmune fibrotic diseases.
    Fenoglio D; Bernuzzi F; Battaglia F; Parodi A; Kalli F; Negrini S; De Palma R; Invernizzi P; Filaci G
    Autoimmun Rev; 2012 Dec; 12(2):300-4. PubMed ID: 22634708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease Manifestation and Inflammatory Activity as Modulators of Th17/Treg Balance and RORC/FoxP3 Methylation in Systemic Sclerosis.
    Almanzar G; Klein M; Schmalzing M; Hilligardt D; El Hajj N; Kneitz H; Wild V; Rosenwald A; Benoit S; Hamm H; Tony HP; Haaf T; Goebeler M; Prelog M
    Int Arch Allergy Immunol; 2016; 171(2):141-154. PubMed ID: 27902985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease.
    Truchetet ME; Brembilla NC; Montanari E; Allanore Y; Chizzolini C
    Arthritis Res Ther; 2011; 13(5):R166. PubMed ID: 21996293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absolute decrease in regulatory T cells and low-dose interleukin-2 therapy: restoring and expanding regulatory T cells to treat systemic sclerosis: a 24-week study.
    Yu Z; Cheng H; Ding T; Liang Y; Yan C; Gao C; Wen H
    Clin Exp Dermatol; 2022 Dec; 47(12):2188-2195. PubMed ID: 36184784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasticity of Treg and imbalance of Treg/Th17 cells in patients with systemic sclerosis modified by FK506.
    Liu X; Wu Y; Li M; Hao J; Wang Q; Zeng X
    Int J Immunopathol Pharmacol; 2021; 35():2058738421998086. PubMed ID: 33631989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated frequencies of CD4(+) IL-21(+) T, CD4(+) IL-21R(+) T and IL-21(+) Th17 cells, and increased levels of IL-21 in bleomycin-induced mice may be associated with dermal and pulmonary inflammation and fibrosis.
    Lei L; He ZY; Zhao C; Sun XJ; Zhong XN
    Int J Rheum Dis; 2016 Apr; 19(4):392-404. PubMed ID: 25545680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis.
    Baraut J; Michel L; Verrecchia F; Farge D
    Autoimmun Rev; 2010 Dec; 10(2):65-73. PubMed ID: 20713187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imbalance toward TFH 1 cells playing a role in aberrant B cell differentiation in systemic sclerosis.
    Ly NTM; Ueda-Hayakawa I; Nguyen CTH; Huynh TNM; Kishimoto I; Fujimoto M; Okamoto H
    Rheumatology (Oxford); 2021 Mar; 60(3):1553-1562. PubMed ID: 33175976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphocyte subset abnormalities in early diffuse cutaneous systemic sclerosis.
    Fox DA; Lundy SK; Whitfield ML; Berrocal V; Campbell P; Rasmussen S; Ohara R; Stinson A; Gurrea-Rubio M; Wiewiora E; Spino C; Bush E; Furst D; Pillai S; Khanna D
    Arthritis Res Ther; 2021 Jan; 23(1):10. PubMed ID: 33407866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T and NK Cell Phenotypic Abnormalities in Systemic Sclerosis: a Cohort Study and a Comprehensive Literature Review.
    Almeida I; Silva SV; Fonseca AR; Silva I; Vasconcelos C; Lima M
    Clin Rev Allergy Immunol; 2015 Dec; 49(3):347-69. PubMed ID: 26445774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunomodulating role of the JAKs inhibitor tofacitinib in a mouse model of bleomycin-induced scleroderma.
    Aung WW; Wang C; Xibei J; Horii M; Mizumaki K; Kano M; Okamura A; Kobayashi T; Matsushita T
    J Dermatol Sci; 2021 Mar; 101(3):174-184. PubMed ID: 33451905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.